A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.

被引：7

作者：

Kaufman, Howard

Wang, Jiafeng

Curti, Brendan D.

Clark, Joseph

Ernstoff, Marc S.

Silk, Ann

Mehnert, Janice M.

Zloza, Andrew

Shih, Joe

McDermott, David F.

机构：

[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[3] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA

[4] Loyola Univ, Med Ctr, Maywood, IL 60153 USA

[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA

[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.tps3095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3095

引用

页数：1

共 50 条

[31] NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma-Efficacy and biomarker study
Ashraf, Madeeha
Kirkwood, John M.
Ernstoff, Marc S.
Abdul-Hassan, Hussein Tawbl
Frankel, Paul Henry
Ruel, Nora
Kendra, Karl Lynn
Olencki, Thomas
Khushalani, NIkhil I.
Logan, Theodore F.
Margolin, Kim Allyson
Chen, Alice P.
Tarhini, Ahmad A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
O'Day, S.
Hodi, F. S.
McDermott, D. F.
Weber, R. W.
Sosman, J. A.
Haanen, J. B.
Zhu, X.
Yellin, M. J.
Hoos, A.
Urba, W. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[33] Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2
Brian Khong
Benjamin O. Lawson
Junjie Ma
Cheryl McGovern
Joan K. Van Atta
Abhijit Ray
Hung T. Khong
BMC Cancer, 18
[34] A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma.
Kudchadkar, Ragini Reiney
Gibney, Geoffrey Thomas
Dorman, Denise
Merek, Stephanie
Ramadan, Howida
Chen, Ann
Weber, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[35] Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2
Khong, Brian
Lawson, Benjamin O.
Ma, Junjie
McGovern, Cheryl
Van Atta, Joan K.
Ray, Abhijit
Khong, Hung T.
BMC CANCER, 2018, 18
[36] Prognostic factors determining long term survival of patients with unresectable stage III and stage IV metostatic melanoma (MM) treated with combination therapy or IL-2 based biochemotherapy (BCC).
Bedikian, AY
Johnson, MM
Broemeling, LD
Papadopoulos, NE
Kim, KBS
Camacho, LH
Hwu, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 721S - 721S
[37] Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma
McDermott, D.
Sosman, J. A.
Hodi, F. S.
Gonzalez, R.
Linette, G.
Richards, J.
Jakub, J. K.
Beeram, M.
Patel, K.
Hersch, E.
EJC SUPPLEMENTS, 2007, 5 (04): : 396 - 396
[38] Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma
Perez, D. G.
Suman, V.
Amatruda, T.
Gornet, M.
Morton, R.
Jilani, S.
Constantinou, C.
Egner, J.
Markovic, S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[39] A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma.
Aamdal, S.
Dueland, S.
Engebraaten, O.
Owre, K.
Dyrhaug, M.
Trachsel, S.
Gaudernack, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
[40] Phase II trial of high-dose bolus (HOB) IL-2 in patients with metastatic melanoma (MM) who haveprogressed after biochemotherapy (BCT): Updated results.
Agarwala, SS
Tarhini, A
Gooding, W
Cai, C
Kirkwood, JM
Stover, LL
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 722S - 722S

← 1 2 3 4 5 →